Beijing Tiantan Biological Products Co., Ltd.
600161
Peringkat dalam Saham
#4320
Beijing Tiantan Biological Products Co., Ltd., established in 1998 and... Beijing Tiantan Biological Products Co., Ltd., established in 1998 and headquartered in Beijing, China, is actively involved in the full spectrum of blood product operations within China. This includes pioneering research and development, manufacturing, sales, and providing consultancy services. Its comprehensive product line features critical blood-derived medicines such as intravenous immunoglobulin, human albumin, and various specialized human immunoglobulins for conditions like hepatitis B (both standard and freeze-dried formulations) and tetanus, alongside other general human immunoglobulin preparations and intravenous blood system solutions. The company operates as a subsidiary of China National Biotec Group Company Limited.
Harga Saham
$1.81
Kapitalisasi Pasar
$3.59B
Perubahan (1 hari)
-0.90%
Perubahan (1 tahun)
-32.39%
Negara
CN
Perdagangan Beijing Tiantan Biological Products Co., Ltd. (600161)
Kategori
Healthcare
Laba untuk Beijing Tiantan Biological Products Co., Ltd. (600161)
Laba pada 2026 TTM: 0
Menurut laporan keuangan terbaru dari Beijing Tiantan Biological Products Co., Ltd., laba saat ini perusahaan adalah 0. Pada tahun 2026, perusahaan memperoleh laba sebesar 0, sama dengan laba tahun 2026 sebesar 0. Laba yang ditampilkan di halaman ini adalah laba sebelum bunga dan pajak, atau disebut juga EBIT.
Riwayat laba untuk Beijing Tiantan Biological Products Co., Ltd. dari 2001 hingga 2026
Laba pada akhir setiap tahun
| Tahun | Laba | Mengubah |
|---|---|---|
| 2025 | $260.52M | -25.35% |
| 2024 | $348.98M | 37.34% |
| 2023 | $254.09M | 22.89% |
| 2022 | $206.77M | 5.90% |
| 2021 | $195.25M | 15.45% |
| 2020 | $169.13M | 12.87% |
| 2019 | $149.85M | 18.76% |
| 2018 | $126.18M | -46.94% |
| 2017 | $237.80M | 345.91% |
| 2016 | $53.33M | 74.97% |
| 2015 | $30.48M | -37.81% |
| 2014 | $49.01M | -45.63% |
| 2013 | $90.14M | 26.29% |
| 2012 | $71.38M | 31.58% |
| 2011 | $54.25M | 32.45% |
| 2010 | $40.96M | -20.34% |
| 2009 | $51.42M | 51.23% |
| 2008 | $34.00M | 38.09% |
| 2007 | $24.62M | 53.52% |
| 2006 | $16.04M | 54.94% |
| 2005 | $10.35M | 53.69% |
| 2004 | $6.73M | 8.91% |
| 2003 | $6.18M | 14.01% |
| 2002 | $5.42M | 10.09% |
| 2001 | $4.93M | 0.00% |
Laba untuk perusahaan serupa atau pesaing
| Perusahaan | Laba | Perbedaan Laba | Negara |
|---|---|---|---|
| $5.27B | - |
US
|
|
| $-3.09B | - |
US
|
|
| $-4.02B | - |
AU
|
|
| $1.95B | - |
NL
|
|
| - | - |
CH
|
